EAU 2018: Natural History of Collecting Duct Carcinoma: A Unique Multi-Institutional Study with a Centrally-Reviewed Pathology
The authors of this study note that most previously published CDRCC series are population-based or multi-institutional studies, but lack a central review by a dedicated pathologist, which may have led to flaws in case identification. As such, they report comprehensive clinical features of CDRCC based a multi-institutional study, but do so with a central review of pathology by a dedicated GU pathologist. They identified patients with histologically confirmed CDRCC in 7 participating French institutions, which were then sent and reviewed by GU pathology at a single institution. After diagnosis confirmation, clinical data were collected anonymously in every institution for analysis.
They then presented the clinical data in their case series of the 29 patients. Table 1 summarized the basic patient and disease characteristics – mean age 54, 72% male, 62% metastatic at diagnosis, 80% underwent radical nephrectomy, and only 38% received chemotherapy (6% targeted therapy).
In their age distribution, they noted a bimodal distribution focused around age 32 and 63.
In terms of survival, 2-year OS was just 7%, further highlighting the aggressive nature of this subtype. As expected, older age and metastatic disease at diagnosis were associated with worse survival. However, “old” age was not defined.
While this data does not present much new information compared to prior series, it is strengthened by the central GU pathology review. The clinical outcomes are not much different than previously reported.
Presented by: I. Ouzaid
Co-Authors: Ouzaid I.1 , Comperat E.2 , Roupr.t M.3 , Rioux-Leclerc N.4 , Descotes J.5 , Verkarre V.6 , Bernhard J-C.7 , Barth.l.my P.8 , Malouf G.9
Author Information:
1. Bichat Hospital, Dept. of Urology, Paris , France
2. Tenon Hospital, Dept. of Pathology, Paris, France
3. CHU Piti.-Salp.tri.re, Dept. of Urology, Paris, France
4. CHU Rennes, Dept. of Pathology, Rennes, France
5. CHU Grenoble, Dept. of Urology, Grenoble, France
6. CHU Georges Pompidou, Dept. of Pathology, Paris, France
7. CHU Bordeaux, Dept. of Urology, Bordeaux, France
8. CHU Strasbourg, Dept. of Medical Oncology, Strasbourg, France
9. CHU Piti.-Salp.tri.re, Dept. of Medical Oncology, Paris, France
Written by: Thenappan Chandrasekar, MD Clinical Fellow, University of Toronto, twitter: @tchandra_uromd at the 2018 European Association of Urology Meeting EAU18, 16-20 March, 2018 Copenhagen, Denmark